盧琳琳:女，1985年生，於2014年6月博士畢業，博士就讀於南方醫科大學藥學專業。在河南大學藥學院獲碩士學位，曾在中國科學院生物物理研究所和美國威斯康星醫學院研究所作訪問學者。主要研究領域為腫瘤生物學。研究方向為1）肝癌的發生與藥物代謝酶變化的相關性及機理：發現肝組織中的CYP3A4藥物代謝酶的活性及功能顯著下降，致癌因子如P53等嚴重影響了CYP3A4酶的合成與轉錄。同時，B肝病毒中HBx蛋白亦通過影響核受體（如PXR和RXR）對CYP3A4的調控作用而使CYP3A4在肝癌組織中的表達顯著下降。CYP3A4在肝癌組織的變化可早期預警肝的癌變過程。2）腫瘤的靶向治療及機制：研究了抗腫瘤藥物納米製劑治療腫瘤的靶向性、毒性以及抗癌機理。3）中草藥預防肺癌發生及早期治療的作用及分子機制研究。建立了肺癌癌前病變以及肺癌易感基因動物及細胞模型，篩選與評價了中草藥及其複方製劑預防肺癌發生的作用、以及對早期肺癌的治療作用等，同時，亦研究了中草藥預防肺癌發生作用的靶點如microRNA等及其分子機理。參加國家自然科學基金國際合作重大項目、國家自然科學基金－廣東省聯合基金重點項目和國家973計畫分課題各1項。
研究方向
● 在由B肝病毒引起的肝細胞癌中，肝臟藥物代謝酶下調的機制研究
● 中藥對化學誘導肺癌及肝癌的預防作用及機制研究
發表論文
[1] Zhu LJ, Lu LL, Wu JJ, Wang Y, Guo ES, Hu M, Liu ZQ.* The influences of aconitine, an active/toxic alkaloid from aconitum, on the oral pharmacokinetics of CYP3A probe drug buspirone in rats. Drug Metabolism Letters, doi: 10.2174/1872312808666140505162139, 2014.
[2] YeL, YangXS, GuoES, Cheng WY, Lu LL , WangY, PengPJ, YanTM, Zhou FY, Liu ZQ, Sorafenib metabolism is significantly altered in the liver tumor tissue of hepatocellular carcinoma patient.PloS One, 9(5):e96664
[3] Yang XS, Wu JJ, Lu LL, Zhu LJ, Liu ZQ*. Progress of Pharmacokinetic Study on Fuzi. World Chinese Medicine. 2014, 9(2): 171-174
[4] Lu LL, Shi J, Li Q, Peng XJ, Dong LN, Ye L, Dai PM, Wang Y, Guo ES, Zhou FY, Liu ZQ. Effects of Liver Diseases on Drug-metabolizing Enzymes: Implications for Drug Fate Alterations and Nano-therapeutic Openings. Current Medicinal Chemistry. 2013, Accepted.
[5] Ye L, Yang XS, Lu LL, Yan TM, Dong LN, Peng XJ, Shi J, Liu ZQ. Monoester-diterpene aconitum alkaloids metabolism in human liver microsomes: predominant role of CYP3A4 and CYP3A5. Evidence-Based Complementary and Alternative Medicine, 2013, doi: 10.1155/ 2013/941093.
[6] Ye L, Lu LL, Zeng S, Chen WY, Feng Q, Liu W, Tang L, Liu ZQ. Potential role of ATP-binding cassette transporters in the intestinal transport of rhein. Food and Chemical Toxicology, 2013, 58:301-5.
[7] Qin L, Jin L, Lu LL, Lu X, Zhang C, Zhang F, Liang W. Naringenin reduces lung metastasis in a breast cancer resection model. Protein Cell. 2011, 2(6):507-16.
[8] Du GJ, Lin HH, Yang YM, Zhang S, Wu XC, Wang M, Ji LY, Lu LL, Yu LJ, Han G. Dietary quercetin combining intratumoral doxorubicin injection synergistically induces rejection of established breast cancer in mice. International Immunopharmacology. 2010,10 (5): 819–826.
[9] Du GJ, Lin HH, Wang M, Zhang S, Lu LL, Ji LY, Yu LJ.Quercetin greatly improved therapeutic index of doxorubicin against 4T1 breast cancer by its opposing effects on HIF-1αin tumor and normal cells.Cancer Chemother Pharmacol. 2010, 4(65):277–287.
[10] Du GJ, Han G, Zhang S, Lin HH, Wu XC, Wang M, Ji LY, Lu LL, Yu LJ, Liang W. Baicalin suppresses lung carcinoma and lung metastasis by SOD mimic and HIF-1α inhibition. European Journal of Pharmacology. 2010, 5(10):121–130.
